Skip to main content
Log in

Pharmacokinetics and tolerance of a new penem antibiotic, FCE 22101, in healthy volunteers after a single intravenous dose

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The clinical tolerance and pharmacokinetics of FCE 22101 (sodium (5R, 6S)-6-[(1R)-hydroxyethyl]-2-carbamoyloxymethyl-2-penem-3-carboxylate), a new penem antibiotic, have been studied after giving a single i.v. dose of 4 mg·kg−1 to ten healthy male volunteers. The pharmacokinetics was estimated according to a two-compartment open model. The peak plasma concentration (Cmax) was 15.5 (1.08) µg·ml−1, mean (SEM). FCE 22101 was rapidly cleared from the systemic circulation [\(t_{1/2\lambda _z } \)=44.2 (4.2) min; CL=7.21 (0.47) ml·kg−1·min−1]. The mean apparent volume of distribution at steady-state was 246 (16.9) ml·kg−1. The mean residence time relative to the 10 min infusion was 39.4 (1.5)min. Urinary recovery of FCE 22101 showed wide inter-subject variation, ranging from 10.2 to 53.6% of the dose. No subject complained of adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Franceschi G, Foglio M, Alpegiani M, Battistini C, Bedeschi A, Perrone E, Zarini F, Arcamone F, Della Bruna C, Sanfilippo A (1983) Synthesis and biological properties of sodium (5R, 6S, 8R)-6-α-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891. J Antibiot 36:938–941

    Google Scholar 

  2. Wise R, Andrews JM, Danks G (1983) Comparison of in vitro activity of FCE 22101, a new penem, with those of other β-lactam antibiotics. Antimicrob Agents Chemother 24: 909–914

    Google Scholar 

  3. Hitzenberger G, Strolin Benedetti M, Jannuzzo MG, Silvestri S, Moro E, Frigerio E, Sassella D (1989) Pharmacokinetics and clinical tolerability of FCE 22101, a new penem antibiotic in healthy volunteers after a single i.m. administration. Chemioterapia 8 [Suppl] Proceedings of 6th Mediterranean Congress of Chemotherapy, Taormina, Italy (in press)

  4. Norrby SR, Alesting K, Ferber F, Huber JL, Jones HK, Kahan FM, Meisinger MAP, Rogers JD (1983) Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother 23: 293–299

    Google Scholar 

  5. Jusko WJ, Gibaldi M (1972) Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 61: 1270–1273

    Google Scholar 

  6. Cassinelli G, Corigli R, Orezzi P, Ventrella G, Bedeschi A, Perrone E, Borghi D, Franceschi G (1988) Structure determination of primary renal metabolite of the penem FCE 22101. J Antibiot 41: 984–987

    Google Scholar 

  7. Jannuzzo MG, Vaiani R, Strolin Benedetti M, Carnovali M, Cassinelli G, Corigli R (1989) Pharmacokinetics and metabolism of FCE 22101, a new penem antibiotic. Chemioterapia 8 [Suppl] Proceedings of 6th Mediterranean Congress of Chemotherapy. Taormina, Italy (in press)

  8. Hajdu R, Hayase K, Sundelof J, Hara K, Kropp H, Kahan F (1985) Cilastatin-sensitive lactamase active on carbapenem and penem antibiotics in the lung of rodents. In: Ishigami J (ed) Recent advances in chemotherapy. Proceedings 14th International Congress of Chemotherapy, University of Tokio Press, Tokio, pp 1211–1212

    Google Scholar 

  9. Norrby SR, Biornegard B, Febert F, Jones KH (1983) Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 12 [Suppl D]: 109–124

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jannuzzo, M.G., Mandelli, M., Strolin Benedetti, M. et al. Pharmacokinetics and tolerance of a new penem antibiotic, FCE 22101, in healthy volunteers after a single intravenous dose. Eur J Clin Pharmacol 36, 633–635 (1989). https://doi.org/10.1007/BF00637750

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00637750

Key words

Navigation